Here are four updates on GI companies from the past week:
Takeda, Sweden-based Karolinska Institutet and The Structural Genomics Consortium entered into a precompetitive and proprietary collaboration agreement to research and test potential intervention points for inflammatory bowel disease.
Takeda Pharmaceuticals U.S.A. donated $100,000 to local and regional nonprofits as part of its annual Takeda Cares Day.
EnteroMedics acquired ReShape Medical and its ReShape Dual Weight Loss Balloon, a minimally invasive intragastric balloon system.
TransMed7, a medical device company, appointed Michael Demeure, MD, chair of its endocrine and gastrointestinal health team.